Insulin-like growth factor 1 receptor

Actually, the molecule that I'm working on, which is an mTORC1 inhibitor, might be some of that fix.

There's another product that I was just a judge at this competition, and it's called the Aging Code Summit, and somebody had an IGFR1 inhibitor.

And that one showed good response against graying in mice.

So where mice are not humans and things don't often translate, but there is some good data for graying.

The aim of this review is to summarize the changing in understanding and framing of this multifaceted disease, in particular highlighting the current transition from a phenotype-first to a genotype-first framework for diagnosis and management.

In a viewpoint article entitled Hypertension With Defective IGF-1R/PI3K Signaling May Trigger Atrial Cardiomyopathy, Atrial Fibrillation, and Stroke, Julia McMullan, Renata Schnabel, and Ben Freedman from the University of Sydney in Australia and the University Medical Center Hamburg-Eppendorf in Germany aim to examine how hypertension and impaired insulin-like growth factor one receptor phosphoinositide three kinase, or IGF-1R/PI3K, signaling may contribute to atrial cardiomyopathy, or ATCM, and the development of atrial fibrillation, or AF, heart failure, or HF, and stroke.

Hypertension is a potent risk factor.

In particular, hypertension is the single biggest contributor to AF, HF, and stroke-related mortality.

Repeat episodes of acute/chronic blood pressure elevation lead to progressive functional and morphological remodeling of the atria, termed atrial ATCM.

Despite knowledge that hypertension increases the risk of stroke, AF, and HF, the mechanisms underlying the central role of BP in this relationship are not well understood.

Here, the authors review the evidence that the IGF-1R/PI3K signaling pathway plays key roles in mediating cardiac protection, BP regulation, and normal atrial biology and propose that hypertension in a setting of defective IGF-1R/PI3K signaling represents a key trigger for the development of ATCM and increased risk of AF, HF, and stroke.

Of clinical relevance, IGF-1R/PI3K signaling is reduced/defective with risk factors for AF and HF, including aging, hypertension, obesity, diabetes, and physical inactivity.

Thyroid eye disease is an autoimmune condition that can cause swelling and bulging around the eyes, pain, and in severe cases, vision loss.

Linacitinib targets IGF-1R, the same pathway addressed by the approved infused antibodies TEPEZZA and LIMVOO.

Its potential distinction is a pill taken twice a day.

The target is already used in treatment.

Two clinical-stage biopharma financings closed this week as investors back next-generation autoimmune and oncology candidates.

Sling Therapeutics raises one hundred and twenty-three million dollars in a Series C led by Forbion, with participation from TPG Life Sciences Innovations and new investor Sectoral Asset Management to advance linsitinib, an oral IGF-1R inhibitor and the only one in late-stage development through the Phase Three ORBIT trial in thyroid eye disease.

Separately, Circle Pharma raises ninety-two point five million dollars in a Series E led by the Column Group with Eli Lilly and Company among the investors to advance CID-one sixty-five, a first-in-class oral macrocyclic cyclin D1RXL inhibitor moving toward early clinical development in ER-positive breast cancer.

Finally, Phil Ford, vice president and general manager of global medical affairs and HCP engagement at IQVIA, argues that pharma companies need to replace their linear medical content pipeline with a continuous loop connecting creation, review, distribution, and measurement.